vs
ABVC BIOPHARMA, INC.（ABVC）与Arcellx, Inc.（ACLX）财务数据对比。点击上方公司名可切换其他公司
Arcellx, Inc.的季度营收约是ABVC BIOPHARMA, INC.的2.1倍（$1.7M vs $796.0K）。ABVC BIOPHARMA, INC.净利率更高（-256.6% vs -3513.4%，领先3256.8%）。ABVC BIOPHARMA, INC.同比增速更快（104.5% vs -89.2%）。过去两年ABVC BIOPHARMA, INC.的营收复合增速更高（1041.5% vs -79.5%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
ABVC vs ACLX — 直观对比
营收规模更大
ACLX
是对方的2.1倍
$796.0K
营收增速更快
ABVC
高出193.6%
-89.2%
净利率更高
ABVC
高出3256.8%
-3513.4%
两年增速更快
ABVC
近两年复合增速
-79.5%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $1.7M |
| 净利润 | $-2.0M | $-58.1M |
| 毛利率 | 100.0% | — |
| 营业利润率 | -246.8% | -3850.2% |
| 净利率 | -256.6% | -3513.4% |
| 营收同比 | 104.5% | -89.2% |
| 净利润同比 | -417.4% | -23.4% |
| 每股收益（稀释后） | $-0.09 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCACLX
| Q4 25 | — | $1.7M | ||
| Q3 25 | $796.0K | $4.9M | ||
| Q2 25 | — | $7.6M | ||
| Q1 25 | — | $8.1M | ||
| Q4 24 | $2.0K | $15.3M | ||
| Q3 24 | $389.3K | $26.0M | ||
| Q2 24 | $117.1K | $27.4M | ||
| Q1 24 | $1.2K | $39.3M |
净利润ABVCACLX
| Q4 25 | — | $-58.1M | ||
| Q3 25 | $-2.0M | $-55.8M | ||
| Q2 25 | — | $-52.8M | ||
| Q1 25 | — | $-62.3M | ||
| Q4 24 | $-731.6K | $-47.1M | ||
| Q3 24 | $-394.8K | $-25.9M | ||
| Q2 24 | $-942.3K | $-27.2M | ||
| Q1 24 | $-2.8M | $-7.2M |
毛利率ABVCACLX
| Q4 25 | — | — | ||
| Q3 25 | 100.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 100.0% | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — | ||
| Q1 24 | 77.0% | — |
营业利润率ABVCACLX
| Q4 25 | — | -3850.2% | ||
| Q3 25 | -246.8% | -1248.3% | ||
| Q2 25 | — | -777.4% | ||
| Q1 25 | — | -847.6% | ||
| Q4 24 | -35837.4% | -348.2% | ||
| Q3 24 | -77.7% | -129.1% | ||
| Q2 24 | -734.2% | -127.8% | ||
| Q1 24 | -235539.8% | -40.3% |
净利率ABVCACLX
| Q4 25 | — | -3513.4% | ||
| Q3 25 | -256.6% | -1127.1% | ||
| Q2 25 | — | -698.6% | ||
| Q1 25 | — | -766.0% | ||
| Q4 24 | -37211.3% | -308.4% | ||
| Q3 24 | -101.4% | -99.4% | ||
| Q2 24 | -804.4% | -99.3% | ||
| Q1 24 | -235203.2% | -18.3% |
每股收益（稀释后）ABVCACLX
| Q4 25 | — | $-1.01 | ||
| Q3 25 | $-0.09 | $-0.99 | ||
| Q2 25 | — | $-0.94 | ||
| Q1 25 | — | $-1.13 | ||
| Q4 24 | $-0.02 | $-0.87 | ||
| Q3 24 | $-0.03 | $-0.48 | ||
| Q2 24 | $-0.08 | $-0.51 | ||
| Q1 24 | $-0.29 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $450.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.1M | $402.4M |
| 总资产 | $21.2M | $604.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABVCACLX
| Q4 25 | — | $450.3M | ||
| Q3 25 | $257.2K | $461.4M | ||
| Q2 25 | — | $453.1M | ||
| Q1 25 | — | $543.3M | ||
| Q4 24 | $313.1K | $587.4M | ||
| Q3 24 | $208.2K | $574.3M | ||
| Q2 24 | $200.0K | $516.7M | ||
| Q1 24 | $106.4K | $573.9M |
股东权益ABVCACLX
| Q4 25 | — | $402.4M | ||
| Q3 25 | $12.1M | $440.8M | ||
| Q2 25 | — | $392.2M | ||
| Q1 25 | — | $416.9M | ||
| Q4 24 | $1.2M | $454.8M | ||
| Q3 24 | $1.6M | $483.0M | ||
| Q2 24 | $1.8M | $487.2M | ||
| Q1 24 | $1.7M | $496.6M |
总资产ABVCACLX
| Q4 25 | — | $604.0M | ||
| Q3 25 | $21.2M | $655.9M | ||
| Q2 25 | — | $619.1M | ||
| Q1 25 | — | $648.1M | ||
| Q4 24 | $7.5M | $711.3M | ||
| Q3 24 | $7.8M | $764.9M | ||
| Q2 24 | $8.0M | $734.3M | ||
| Q1 24 | $8.0M | $779.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | $-58.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-58.9M |
| 自由现金流率自由现金流/营收 | — | -3563.4% |
| 资本支出强度资本支出/营收 | — | 46.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-212.6M |
8季度趋势，按日历期对齐
经营现金流ABVCACLX
| Q4 25 | — | $-58.2M | ||
| Q3 25 | $-964.7K | $-49.2M | ||
| Q2 25 | — | $-39.7M | ||
| Q1 25 | — | $-63.1M | ||
| Q4 24 | $-702.1K | $-46.0M | ||
| Q3 24 | $60.2K | $30.7M | ||
| Q2 24 | $-211.4K | $-36.2M | ||
| Q1 24 | $-955.8K | $-31.9M |
自由现金流ABVCACLX
| Q4 25 | — | $-58.9M | ||
| Q3 25 | — | $-49.5M | ||
| Q2 25 | — | $-40.2M | ||
| Q1 25 | — | $-63.9M | ||
| Q4 24 | — | $-47.5M | ||
| Q3 24 | — | $28.4M | ||
| Q2 24 | — | $-39.5M | ||
| Q1 24 | — | $-38.3M |
自由现金流率ABVCACLX
| Q4 25 | — | -3563.4% | ||
| Q3 25 | — | -1000.3% | ||
| Q2 25 | — | -532.4% | ||
| Q1 25 | — | -786.4% | ||
| Q4 24 | — | -311.3% | ||
| Q3 24 | — | 109.2% | ||
| Q2 24 | — | -144.1% | ||
| Q1 24 | — | -97.7% |
资本支出强度ABVCACLX
| Q4 25 | — | 46.2% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | — | 9.6% | ||
| Q4 24 | — | 9.8% | ||
| Q3 24 | — | 8.8% | ||
| Q2 24 | — | 11.7% | ||
| Q1 24 | — | 16.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
